| 郭 刚,张璐璐,侯英娟,赵 斌,王 静.舒血宁注射液联合胞磷胆碱钠对脑梗死患者神经功能及血清IGF-1、vWF、HIF-1α水平的影响[J].,2019,19(24):4768-4771 |
| 舒血宁注射液联合胞磷胆碱钠对脑梗死患者神经功能及血清IGF-1、vWF、HIF-1α水平的影响 |
| Effect of Shuxuening Injection Combined with Citicoline Sodium on the Neurological Function and the Levels of Serum IGF-1, vWF and HIF-1α in Patients with Cerebral Infarction |
| 投稿时间：2019-04-28 修订日期：2019-05-23 |
| DOI：10.13241/j.cnki.pmb.2019.24.039 |
| 中文关键词: 舒血宁注射液 胞磷胆碱钠 脑梗死 神经功能 日常生活能力 |
| 英文关键词: Shuxuening injection Citicoline sodium Cerebral infarction Beurological function Activities of daily living |
| 基金项目:陕西省重点研发计划项目(2018SF-219) |
|
| 摘要点击次数: 744 |
| 全文下载次数: 332 |
| 中文摘要: |
| 摘要 目的：研究舒血宁注射液联合胞磷胆碱钠对脑梗死患者神经功能及血清胰岛素样生长因子(IGF-1)、血浆血管性病友因子(vWF)、缺氧诱导因子-1α(HIF-1α)水平的影响。方法：收集2014年3月至2016年3月我院收治的120例脑梗死患者，按抽签法分为对照组和实验组，每组各60例。两组均采用基础治疗，对照组在此基础上采用胞磷胆碱钠治疗，每次2粒，每天3次；实验组在对照组的基础上采用舒血宁注射液治疗，每次5 mL，加入0.9%生理盐水250 mL中混合后进行静脉滴注，每天1次。两组治疗疗程均为2周。对比两组治疗前后神经功能缺损评分(NIHSS)、日常生活能力(ADL)，血清IGF-1、vWF、HIF-α水平的变化，不良反应的发生情况及治疗疗效。结果：治疗后，实验组总有效率显著高于对照组[91.66%(55/60) vs. 71.66%(43/60)](P＜0.05)，NIHSS评分显著低于对照组[(7.01±1.23)分 vs. (10.52±1.98)分](P＜0.05)，ADL评分显著高于对照组[(68.16±5.62)分 vs. (56.20±5.13)分](P＜0.05)；血清IGF-1水平显著高于对照组[(174.29±27.35)IU/mL vs. (152.08±25.29)IU/mL](P＜0.05)，血清vWF、HIF-α水平显著低于对照组[(5.63±1.21)mg/L vs. (11.92±1.35)mg/L，(14.21±3.11)μmol/L vs. (20.16±3.89)μmol/L](P＜0.05)；两组不良反应的发生率比较无显著差异(P＞0.05)。结论：舒血宁注射液联合胞磷胆碱钠治疗脑梗死的临床疗效显著优于单用胞磷胆碱钠治疗，其可有效改善患者的神经功能，恢复脑组织功能，可能与其效减轻炎症反应及抑制氧化应激反应有关。 |
| 英文摘要: |
| ABSTRACT Objective: To research the effect of Shuxuening injection combined with Citicoline Sodium on the neurological function, levels of serum Insulin-like growth factors-1(IGF-1), von Willebrand factor(vWF) and Hypoxia-inducible factor -1α(HIF-1α) in patients with cerebral infarction. Methods: 120 cases of patients with cerebral infarction were divided into the control group and the experimental group according to the draw method, with 60 cases in each group. Both groups were treated by conventional treatment, the control group was additionally treated by citicoline sodium, 2 tablets each time, 3 times a day. The experimental group was treated by Shuxuening injection on the basis of control group, 5 mL every time, added in 250 mL 0.9% physiological saline, intravenous drip, 1 time a day. Both groups were treated for 2 weeks. The changes of NIHSS, ADL, serum IGF-1, vWF, HIF-α levels before and after treatment, the incidence of adverse reactions and therapeutic efficacy were compared between the two groups. Results: After treatment, the total effective rate in the experimental group was significantly higher than that of the control group[91.66%(55/60) vs.71.66%(43/60)](P＜0.05). The NIHSS score of experimental group was significantly lower than that of the control group[(7.01±1.23)score vs. (10.52±1.98)score](P＜0.05); the ADL score was significantly higher than that of the control group[(68.16±5.62) vs. (56.20±5.13)](P＜0.05); the Serum IGF-1 levels was significantly higher than that of the control group[(174.29±27.35)IU/mL vs. (152.08±25.29)IU/mL](P＜0.05); the levels of vWF, HIF-α in serum were significantly lower than those of the control group[(5.63±1.21) mg/L vs. (11.92±1.35) mg/L, (14.21±3.11) μmol/L vs. (20.16±3.89) μmol/L](P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: The clinical effect of Shuxuening injection combined with citicoline sodium is significantly better than that of citicoline sodium alone in the treatment of cerebral infarction. It can effectively improve the neurological function of patients and restore the function of brain, which may be related to the alleviation of inflammatory reaction and inhibition of oxidative stress. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
